Showing 4551-4560 of 4826 results for "".
- Valeant Commences Exchange Offer For Allerganhttps://practicaldermatology.com/news/20140618-valeant_commences_exchange_offer_for_allergan/2459200/Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: VRX) (TSX: VRX) today announced that it has commenced an exchange offer for the common stock of Allergan, Inc. ("Allergan") (NYSE: AGN), taking its May 30th proposal directly to Allergan stockholders. Under the terms of the offer, Allerg
- Valeant Pharmaceuticals Receives FDA Clearance For Restylane Silkhttps://practicaldermatology.com/news/20140616-valeant_pharmaceuticals_receives_fda_clearance_for_restylane_silk/2459205/The FDA issued marketing clearance for Valeant Pharmaceuticals International, Inc.'s Restylane Silk Injectable Gel with 0.3% Lidocaine for submucosal implantation for lip augmentation and dermal implantation for correction of perio
- TruInject Injector Training System Receives Approval of Its Patenthttps://practicaldermatology.com/news/20140613-truinject_injector_training_system_receives_approval_of_its_patent/2459207/One of the key patent applications of TruInject Medical Corporation has been allowed by the US Patent Office. The patent is expected to issue shortly. The patent is for a cosmetic and therapeutic injector training system and is one of many pate
- Provectus Biopharmaceuticals will discuss outline of Phase 3 Clinical Trial Of PV-10 To Treat Melanoma on Conference Callhttps://practicaldermatology.com/news/20140612-provectus_biopharmaceuticals_will_discuss_outline_of_phase_3_clinical_trial_of_pv-10_to_treat_melanoma_on_conference_call/2459208/Provectus Biopharmaceuticals, Inc. has announced that it will hold a conference call on Thursday, June 19, 2014, at 4 pm Eastern Daylight Time. Management will discuss the outline of the Company's proposed Phase 3 study of PV-10 in the treatment of melanoma, developments in the use of PV-
- Allergan Again Unanimously Rejects Valeant's Revised Unsolicited Proposalhttps://practicaldermatology.com/news/20140610-allergan_again_unanimously_rejects_valeants_revised_unsolicited_proposal/2459212/Allergan has once again rejected the revised unsolicited proposal from Valeant and Pershing Square Capital Management, setting the stage for a lengthy hostile takeover battle. Allergan announced Tuesday that its board of directors, after consulting with its independent financial and legal advisors
- Envy Medical Receives Growth Capital Investment from HCP & Companyhttps://practicaldermatology.com/news/20140604-envy_medical_receives_growth_capital_investment_from_hcp__company/2459218/Chicago-based HCP & Company is providing a growth capital investment to Envy Medical to support sales and marketing initiatives, while also allowing the company to accelerate the development and introduction of new skincare offerings designed to meet the growing demand for healthier skin tone, te
- Provectus Biopharmaceuticals, Inc.'s Common Shares Begin Trading on NYSEhttps://practicaldermatology.com/news/20140516-provectus_biopharmaceuticals_incs_common_shares_begin_trading_on_nyse/2459239/Provectus Biopharmaceuticals, Inc. (OTCQB:PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced that its shares will begin trading on the NYSE MKT today, Friday, May 16, 2014. The company's ticker symbol will remain “PVCT” but it will withdraw
- Potential New Diagnostic Tools and Therapies for Melanoma in the Foreseeable Futurehttps://practicaldermatology.com/news/20140512-potential_new_diagnostic_tools_and_therapies_for_melanoma_in_the_foreseeable_future/2459241/Oregon State University researchers have identified a biochemical process that may cause normal and healthy skin cells to transform into cancerous melanoma cells. These findings could help predict melanoma exposure and could also lead to future treatments. Melanoma, the deadliest form of
- SkinCeuticals Announces the Launch of its First US Flagship Locationhttps://practicaldermatology.com/news/20140414-skinceuticals_announces_the_launch_of_its_first_us_flagship_location/2459274/SkinCeuticals launched SkinCeuticals Advanced Clinical Spa with Manhattan Dermatology and Cosmetic Surgery, the first flagship location. An exclusive Integrated Skincare treatment menu has been created, featuring comprehensive offerings that range from clinical procedures to
- Sun Pharma Acquires Ranbaxy in a $4 billion US Transactionhttps://practicaldermatology.com/news/20140407-sun_pharma_acquires_ranbaxy_in_a_4_billion_us__transaction/2459276/Sun Pharma will obtain 100% of Ranbaxy in an all stock transaction. The collaboration of these two pharmaceutical companies leads to the fifth largest generics company globally. There will be operations in 65 countries as well as 47 manufacturing facilities across 5 continents.